Christine Fritz
Papers
1
Total Citations
28
H-Index
1
About
Dr. Christine Fritz is a leading oncologist and translational researcher whose work focuses on rare genitourinary malignancies and targeted therapy resistance. Her most impactful contribution centers on inflammatory myofibroblastic tumors (IMTs) of the bladder, particularly those harboring the FN1-ALK gene fusion. In her landmark 2020 study (28 citations), Dr. Fritz demonstrated the variable response of these ALK-rearranged tumors to crizotinib, revealing that not all ALK fusions respond uniformly to first-generation inhibitors. This work has critical implications for precision oncology, as it challenges the assumption that all ALK-driven tumors are equally sensitive to targeted therapy. By documenting a case where an unresectable IMT failed to respond to neoadjuvant crizotinib, she highlighted the need for next-generation ALK inhibitors or alternative strategies in fusion-specific contexts. Dr. Fritz’s research bridges the gap between molecular pathology and clinical decision-making, offering rare but vital insights into the management of ultra-rare tumors. Her findings have been cited by subsequent studies exploring ALK inhibition in sarcomas and bladder neoplasms, underscoring her influence on the field. For students and researchers, Dr. Fritz exemplifies how meticulous case-based research can drive progress in personalized cancer therapy.
Research Focus
Key Achievements
Top Papers
- 1